Biomarker Correlates of Clinical Outcomes from a Global phase 1b Study of JNJ-90014496, CD20/CD19 Bi-Specific Chimeric Antigen Receptor (CAR) T-cell Therapy for Patients with Large B-cell Lymphoma (LBCL)

Key Points

Clinical outcomes correlate with specific biomarkers, indicating potential for more personalized therapy.
The study highlights CD20 and CD19 as key biomarkers in predicting response to CAR T-cell therapy.
Observational analysis across multiple centers evaluated efficacy in large B-cell lymphoma patients.
Findings support the need for biomarker-driven approaches in addressing LBCL treatment strategies.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Global phase 1b study reveals biomarker correlations with clinical outcomes in patients with LBCL, suggesting enhanced therapeutic strategies.

No takes yet. Share an insight, caveat, or question.

Suraneni et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share